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Abstract
Background and methods: HIV-1 cell-to-cell transmission is more efficient than infection of
permissive cells with cell-free particles. The potency of HIV-1 entry inhibitors to inhibit such
transmission is not well known. Herein, we evaluated the efficacy of this new class of antiretrovirals
to block cell-to-cell transmission of HIV-1 in a model of reconstitution of the human placental
trophoblast barrier in vitro.
Results: Our data show that CCR5 antagonists and T20 inhibit the passage of the virus across the
BeWo cell monolayer in contact with PBMCs infected with an R5 (Ba-L) and a dualtropic (A204)
HIV-1 with IC50s in the range of 100 – 5,000 nM for TAK779; 90 to 15,000 nM for SCH-350581
and 3,000 to 20,000 nM for T20. The CXCR4 antagonist AMD3100 is also effective against X4 HIV-
1 infected PBMCs in our model with IC50 comprised between 4 nM and 640 nM. HIV-1 entry
inhibitors are less efficient to block cell-to-cell virus transmission than cell-free HIV-1 infection of
PBMCs and CCR5 antagonists do not prevent PBMC infection by dual tropic HIV-1 in contrast to
cell-to-cell infection in our model.
Surprisingly, T20 (and C34) do not block cell-to-cell transmission of X4 HIV-1 but, rather, increase
80 to 140 fold, compared to control without drug, the passage of the virus across the trophoblast
barrier. Additional experiments suggest that the effect of T20 on BeWo/PBMC-X4 HIV-1 is due to
an increase of effector-target cells fusion.
Conclusion: Our results support further evaluation of HIV-1 coreceptor antagonists, alone or
combined to other antiretrovirals, in a perspective of prevention but warn on the use of T20 in
patients bearing X4 HIV-1 at risk of transmission.
Background
Human Immunodeficiency Virus Type-1 (HIV-1) trans-
mission occurs by direct contact of cell-free virions and
permissive cells, by interaction between infected and
uninfected target cells (cis infection), or by viral transfer in
trans between an uninfected cell (like Dendritic cells or B
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apses [1-3]. For both sexual and mother-to-foetus trans-
missions, infection in cis via cell-to-cell contact was
shown to be more efficient than infection with cell-free
virus [4]. Hence, sexual and mother-to-foetus transmis-
sion occurred, although at lower rates, despite plasma
viral load suppression [5,6]. This observation highlights
the difficulty to fully block HIV-1 cell-to-cell infection and
transmission, even in the presence of neutralizing anti-
bodies or antiretrovirals [7,8].
In the particular case of HIV-1 mother-to-child transmis-
sion (MTCT), remarkable progress has been made since
the use of antiretroviral (ARVs) drugs [9] for prevention,
together with safer obstetrical interventions and babies
formula feeding. Thus, in Europe and North America,
HIV-1 MTCT has been lowered to less than 2% [10-12],
now occurring mainly in utero [13]. In lower income
countries as in Africa and Asia, HIV-1 MTCT remains a
public health issue as more than 90% of the 2,000 chil-
dren infected daily originated from these parts of the
world [14]. Most of these were infected via the mother-to-
child route. This situation is hopefully improving, thanks
to the introduction of ARVs regimen proven efficacious in
clinical trial settings or pilot programmes [15-17].
All ARVs currently used for HIV-1 positive patients care or
for prevention of MTCT (PMTCT) are either nucleosidic
analogs, non-nucleosidic inhibitors of HIV-1 reverse tran-
scriptase or Protease inhibitors. Some of these drugs, like
AZT, have been in use since the beginnings of AIDS ther-
apy twenty years ago. Because of their long term usage,
ARV lead to selection of drug resistant HIV, thus diminish-
ing their efficacy [18]. A fourth category of ARVs has
emerged as HIV-1 entry inhibitors, consisting of corecep-
tors antagonists and fusion inhibitors. T20 (Enfuvirtide®)
is the prototype of fusion inhibitor that is now in routine
clinical practice for a category of patients who had experi-
enced all the available drugs and whose viruses had
become resistant to [19]. The other type of entry inhibi-
tors (CCR5 and CXCR4 antagonists principally) is under
intensive evaluation [20-22]. Some of them have been
evaluated successfully as microbicides against vaginal,
cell-free SHIV, in macaques, conferring a full protection
when used in combination and at high doses, in the mil-
limolar range [23,24]. The potential toxicity of these high
doses of drugs, upon long term use or repeated usage, is
however, yet unknown. Other drugs like Maraviroc have
undergone successful phase IIII clinical trials [25] and are
now cleared by the US FDA and the European Union for
patient's care.
Primary human term placental trophoblast cells and the
placental derived choriocarcinoma cell line BeWo express
very little or not at all surface CD4 molecules, according
to different studies [26,27]. Both cell types naturally
express the two major HIV-1 coreceptors, CCR5 and
CXCR4 on their surfaces [28-31]. Attempts to infect pla-
cental trophoblasts or BeWo cells with cell-free viruses
lead to resistance or unproductive infection, by mecha-
nisms still debated [31,32]. In contrast, placental tro-
phoblast cells are permissive to cell-to-cell infection
[4,33]. We, and others, use single cycle replication VSV-G
pseudotyped HIV-1 to allow viral entry for cell-free virus
infection of BeWo cells [31] or placental explants [34].
Alternatively, our group has developed an in vitro model
of the polarized human trophoblast barrier to study the
mother/fetus interface in vitro in direct contact with HIV-
1 infected PBMCs [4,33] that we used in the present study.
To anticipate the future by evaluating therapeutic and/or
preventive strategies complementary to those existing, we
used in the present study this in vitro model of the human
placental trophoblast barrier to evaluate the potency of
CCR5 inhibitors (TAK779 and SCH-350581), CXCR4
antagonist (AMD3100) and fusion inhibitors (T20 and
C34) to prevent the passage of HIV-1 across a monolayer
of BeWo cells by virus infected PBMCs. Our data show
that CCR5 and fusion inhibitors, in one hand, and the
CXCR4 antagonist AMD3100, in the other hand, effi-
ciently blocked the passage of R5 or R5X4 and X4 HIV-1,
respectively, through the BeWo monolayer. However,
HIV-1 entry inhibitors are less efficient to block cell-to-cell
virus transmission than cell-free HIV-1 infection of
PBMCs and CCR5 antagonists do not prevent PBMC
infection by dual tropic HIV-1 in contrast to cell-to-cell
infection in our model.
Surprisingly, T20 and C34 could not inhibit the passage of
the virus across the BeWo cell monolayer by PBMC
infected with X4 HIV-1. Rather, they increased viral pas-
sage and thus suggest that T20, the unique entry inhibitor
approved for therapy so far, is not efficient to block X4-
HIV-1 transmission in this context of cell-to-cell contact
and raise the question of its potential use in HIV-1 PMTCT
interventions.
Results
Lower efficacy of T20, TAK779, SCH-350581 and 
AMD3100 to block cell-to-cell virus transmission than cell-
free HIV-1 infection
To evaluate the efficacy of the different HIV-1 entry inhib-
itors in blocking the passage of the virus across a human
placental trophoblast barrier in vitro, we compared the
50% inhibitory concentrations (IC50s), of T20, TAK779,
SCH-350581 and AMD3100 determined in the classical
cell-free virus/PBMCs infectivity assay to those in our in
vitro model of the placental barrier using HIV-1 infected
PBMCs in contact with BeWo cells.Page 2 of 18
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the cells expressing CD4 or not, unless otherwise men-
tioned. After 3 hours of contact between BeWo cells and
PBMCs infected with HIV-1 of different phenotypes, indi-
cator PBMCs in the basolateral compartment produced
detectable amounts of p24 antigen, 8 days post-contact
(Figure 1). Large quantities (up to 100 ng/ml) of p24 anti-
gen were detected when R5 or R5X4 virus infected PBMCs
were used for the contact. Lower quantities were detected
when using PBMCs infected with the X4 HIV-1 isolates
LAI and KH025. The contact between infected PBMCs and
BeWo cells led to the passage of HIV-1 across the placental
trophoblast barrier in vitro, independently of the expres-
sion of CD4 on BeWo cells surface. Although the amounts
of HIV-1 p24 antigen were found generally higher in baso-
lateral chambers when CD4 positive BeWo cells were
used, the difference was only statistically significant when
effector PBMCs were infected with HIV-1-LAI and KH025
(p = 0.01 and 0.04 respectively, Mann-Whitney U test).
We next compared the IC50s of T20, TAK779 and SCH-
350581 in infectivity assay with cell-free HIV-1-Ba-L (R5)
and in the two chamber system using PBMCs infected
with the same isolate and BeWo cells. Results from Figure
2A show that of the three drugs tested, SCH-350581 is the
most potent inhibitor of the infection by cell-free HIV-1/
Ba-L with an IC50 of 5 nM, followed by T20 at 20 nM and
finally, TAK779 with an IC50 of 100 nM. Comparison of
IC50s determined in the PBMC infectivity assay and those
observed in the double chamber system shows for HIV-1/
Ba-L an increase for the three drugs tested. Thus, for T20,
this increase was 250 and 1,000 folds for CD4 negative
and positive BeWo cells, respectively. For TAK779, a mod-
erate 1.5 fold increase of IC50 was observed for CD4 neg-
ative BeWo cells, and equivalent potency for CD4 positive
BeWo cells. For SCH-350581, 90 and 110 nM of the drug
was necessary to achieve 50% inhibition of HIV-1 passage
across the monolayer of CD4 negative and positive BeWo
cells, respectively. These concentrations are roughly 20
Basal HIV-1 p24 antigen production by indicator PBMCs in the basolateral chamber of the in vitro trophoblast barrier modelFigure 1
Basal HIV-1 p24 antigen production by indicator PBMCs in the basolateral chamber of the in vitro trophoblast 
barrier model. After 3 h contact between PBMCs infected with the indicated viral isolates (effector cells) and BeWo cells 
(targets), the Transwell® inserts were extensively washed and left in culture in plates containing activated, HIV-1 negative, indi-
cator PBMCs for 5 days. Inserts were then removed, and cultures of indicator PBMCs were continued for 3 more days and 
HIV-1 p24 core antigen was assayed in the supernatants. The figure shows the average (mean ± SD) of at least 2 independent 
experiments performed in triplicates. The grey bars represent target CD4 negative BeWo cells and the black bars represent 
target CD4 positive BeWo cells. The asterix on the top of the bars denotes a statistically significant difference (p = 0.02) by 
Mann-Whitney U test.Page 3 of 18
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Distinct efficacy of entry inhibitors to block cell-free HIV-1 infection and cell-to-cell virus transmissionFigure 2
Distinct efficacy of entry inhibitors to block cell-free HIV-1 infection and cell-to-cell virus transmission. Activated human PBMCs (105) were 
incubated for 30 min with the different entry inhibitors at various concentrations and then infected with HIV-1 Ba-L (R5), A204 (R5X4), LAI (X4) or 
KH025 (X4) for 1 h at 37°C in the presence of drugs at varying doses. After 3 washes, cells were resuspended in RPMI1640 containing IL-2 and the same 
drug they were pre-incubated with. HIV-1 infected PBMCs were then left in culture for 3 days, when the culture supernatants were replaced with 
RPMI1640-IL-2 medium without drug. The cultures were continued for 4 more days and HIV-1 p24 antigen was assayed in the supernatants. For the inhi-
bition of HIV-1 passage by entry inhibitors, BeWo cells (CD4 negative, white bars or CD4 positive, black bars) were pre-incubated for 30 min at 37°C in 
the presence of varying doses of TAK779, SCH-350581, or AMD3100. If T20 or C34 were used as inhibitors, PBMCs infected with different HIV-1 isolates 
were pre-incubated with varying doses of T20 or C34 for 30 minutes before the contact with BeWo cells. At this point, HIV-1 Ba-L, HIV-1 A204, HIV-1 
LAI or HIV-1 KH025 infected PBMCs were added and both cell types were left in contact for 3 h at 37°C. Extensive washes were then performed and the 
Transwell® inserts transferred on new plates containing activated HIV negative indicator PBMCs, without drugs. The inserts were removed 5 days later 
and the culture continued 3 more days, when the HIV-1 p24 core antigen was quantified in the supernatants. The IC50s were determined graphically from 
the titration curves. Figure 2A: comparison of IC50s during the inhibition of cell-free HIV-1 Ba-L infection of PBMC (grey bars), HIV-1 Ba-L/CD4 negative 
BeWo cells (white bars) and HIV-1 Ba-L PBMC/CD4 positive BeWo cells (black bars). Figure 2B: the PBMCs were infected with HIV-1 A204. Figure 2C: 
the PBMCs were infected with HIV-1 LAI or HIV-1 KH025 and the inhibition was achieved by AMD3100.
Retrovirology 2008, 5:31 http://www.retrovirology.com/content/5/1/31times those observed for the inhibition of PBMC infection
with cell-free HIV-1-Ba-L.
Next, we compared the IC50s of T20, TAK779, SCH-
350581, and AMD3100 during infection of PBMCs with
the dualtropic R5X4 HIV-1-A204 and during the contact
between PBMCs infected with the same isolate and BeWo
cells (Figure 2B). Only the fusion inhibitor T20 and the
CXCR4 antagonist AMD3100 were able to inhibit PMBC
infection by this dualtropic HIV-1 isolate. The IC50s were
20 and 4 nM for T20 and AMD3100, respectively. The
CCR5 antagonists TAK779 and SCH-350581 could not
efficiently and in a dose dependent manners inhibit the
infection of PBMCs by this R5X4 HIV-1 isolate. TAK779
inhibited 80% of viral replication at 20 nM followed by
an increase up to the level without drug at 2,000 nM of the
drug. For SCH-350581, the pattern was different as a con-
stant 20% inhibition of viral replication was observed in
the range 10 to 2,000 nM of drug. Failure of CCR5 antag-
onists to prevent PBMC infection by dualtropic HIV-1 has
been reported recently [35]. During the interaction
between PBMCs infected with the A204 HIV-1 isolate and
BeWo cells, all the four drugs potently inhibited viral pas-
sage from the apical to the basolateral sides of the pla-
centa trophoblast barrier. Here again, the concentrations
necessary to achieve 50% inhibition of viral passage were
higher when compared to those observed in cell-free HIV-
1-A204 infection of PBMCs. Hence, for T20 the IC50s
were 3,000 and 8,000 nM for BeWo cells CD4 negative
and positive, respectively. These concentrations were 150
and 400 times higher than those we observed for the inhi-
bition of cell-free A204 infection of PBMCs. For the
CXCR4 antagonist AMD3100, the concentrations needed
for 50% inhibition of HIV-1 A204 passage across the
BeWo cell monolayer were 320 and 720 nM, for the CD4
negative and positive cell lines, respectively (Figure 2B).
On the contrary to what was observed during cell-free
HIV-1-A204 infection of PBMCs, the CCR5 antagonists
TAK779 and SCH-350581 inhibited viral passage upon
cell-to-cell contact, though at high concentrations. Thus,
for TAK779, the IC50s were 5,000 and 100 nM during
PBMC/HIV-1 A204 interaction with BeWo CD4 negative
and positive, respectively. For SCH-350581, the 50%
inhibitory concentrations were even higher: 5,000 and
15,000 nM for BeWo CD4 negative and positive, respec-
tively, in contact with A204 infected PBMCs.
Finally, we compared the IC50s of AMD3100 during the
infectivity assay of PBMCs with cell-free X4 HIV-1-LAI and
HIV-1-KH025 and during the contact between PBMCs
infected with the same isolates and BeWo cells. Results
from Figure 2C indicated that AMD3100 inhibited with
different efficacies PBMC infection by the two X4 HIV-1
isolates. The IC50s observed were 2.4 nM and 400 nM for
HIV-1-LAI and HIV-1-KH025, respectively. The concentra-
tions of AMD3100 necessary to achieve 50% inhibition of
HIV-1-LAI passage across the BeWo cells monolayer were
1.6 and 3 times, for CD4 negative and positive BeWo cells,
respectively, higher than the IC50 required to block cell-
free virus infection of PBMC. Much higher concentrations
of AMD3100 were necessary to reach the 50% inhibitory
concentrations that block HIV-1 KH025 passage across
the BeWo monolayer. IC50s of 320 nM and 640 nM were
observed during the interaction between PBMC infected
with KH025 and CD4 negative and positive BeWo cells,
respectively.
Altogether, these data indicate that HIV-1 entry inhibitors
are less efficient, in vitro, to block cell-to-cell virus trans-
mission than cell-free HIV-1 infection of PBMCs and that
CCR5 antagonists do not prevent PBMC infection by dual
tropic HIV-1 in contrast to cell-to-cell infection in our
model.
The fusion inhibitors T20 and C34 increase the viral 
passage across the BeWo cell line monolayer in contact 
with PBMCs infected with X4 HIV-1 isolates
The fusion inhibitor T20, although efficient in blocking
PBMC infection by cell-free HIV-1-LAI and HIV-1-KH025
with IC50s of 20 and 5 nM respectively, was unable to
inhibit the passage of the virus across the BeWo cells mon-
olayer in contact with PBMCs infected with these X4
viruses. On the contrary, we found that T20 increases by
80 to 140 folds the level of passage without drug of both
viruses across the monolayer of BeWo cells, in a dose-
dependent manner as shown on Figure 3A &3B. This
enhancement started at concentrations of 1,000 nM of
drug and was independent of the presence of CD4 on the
surface of BeWo cells. At 100 nM of T20, 60% of inhibi-
tion of viral passage was observed after the interaction
between HIV-1/LAI infected PBMCs and CD4 positive
BeWo cells (Figure 3A, continuous line), followed by an
increase above the control (without T20) level at 1,000
nM of the drug. Results obtained with a different batch of
PBMCs infected with HIV-1/LAI or HIV-1/KH025 (not
shown) were consistent with those presented herein.
To confirm this result, we also used another fusion inhib-
itor, C34, a 34 amino-acid peptide from HIV-1 heptad
repeat-2 (HR2), like T20, and whose mechanism of action
is similar to T20, but that lacks 12 amino acids at the C-
terminus end of T20. In addition, C34 does not bind cell
membrane on the contrary of T20 [36]. Hence, if the
enhancement we observed was due to BeWo cell mem-
brane disorganisation by T20, C34 should not induce
such increase of viral passage. Results obtained with C34
on cell-free virus (Ba-L and LAI) PBMC infection were
consistent with data from the literature, with IC50s of 5
nM for Ba-L and 0.8 nM for LAI (data not shown). When
C34 was used to block viral passage across the monolayerPage 5 of 18
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The fusion inhibitors T20 and C34 enhance viral passage across the BeWo cell monolayer in contact with PBMCs infected with X4 HIV-1Figure 3
The fusion inhibitors T20 and C34 enhance viral passage across the BeWo cell monolayer in contact with 
PBMCs infected with X4 HIV-1. PBMCs infected with HIV-1 LAI or HIV-1 KH025 isolates were pre-incubated with varying 
doses of T20 or C34 for 30 minutes. Then, HIV-1 LAI or HIV-1 KH025 infected PBMCs were added to the BeWo cell monol-
ayer and were left in contact for 3 h at 37°C. Extensive washes were then performed and the Transwell® inserts transferred on 
new plates containing activated HIV negative indicator PBMCs, without drugs. The inserts were removed 5 days later and the 
culture continued 3 more days, when the HIV-1 p24 core antigen was quantified in the supernatants. The figures show HIV-1 
passage across the model of the trophoblast barrier normalized to the control (without drugs) as a function of T20 (or C34) 
concentration. Continuous line, CD4 positive BeWo cells as target cells; dashed line: CD4 negative BeWo cells as target cells. 
3A: PBMCs infected with HIV-1 LAI as effector cells in the presence of T20; 3B: PBMCs infected with HIV-1 KH025 as effec-
tor cells in the presence of T20 and 3C: PBMCs infected with HIV-1 LAI as effector cells in the presence of C34.
Retrovirology 2008, 5:31 http://www.retrovirology.com/content/5/1/31of BeWo cells in contact with PBMCs infected with HIV-1/
LAI, an increase of viral passage was observed (Figure 3C).
This increase of HIV-1/LAI passage across the BeWo mon-
olayer was stronger when BeWo cells were CD4 negative
(figure 3C, dashed line). In that case, an increase of more
than 100 folds the control level was observed at 100 nM
C34, in contrast to the 1.7–2.3 folds observed with BeWo
CD4 positive cells (Figure 3C, continuous line).
T20 increases fusion between BeWo cells and PBMC 
infected with HIV-1 LAI
To further investigate why the fusion inhibitor enhanced
X4 HIV-1 passage across the BeWo cells monolayer, we
checked if this increase was related to an increase of
BeWo-PBMC cell membranes fusion. To that end, we per-
formed dye transfer experiments using effector PMBCs
infected with HIV-1 LAI loaded with the green cytoplas-
mic dye calcein-AM and BeWo cells as targets, seeded on
slides. Dye transfer from the cytoplasm of the effector cell
to that of the target cell evidenced the fusion between
effector and target cells membranes. Figure 4and 6 show
representative examples of such experiments performed
with CD4 negative and positive BeWo cells, respectively.
The 3 columns represent the 3 different experimental con-
ditions tested as indicated on the top of each of them. The
middle column from figure 4 shows massive intrusion of
green fluorescence into the cytoplasm of target CD4 nega-
tive BeWo cells in the presence of 10 μM T20. This green
fluorescence inside BeWo cells corresponds to the trans-
fer, ensuing cell membrane fusion, of the cytoplasm of
HIV-1 infected effector PBMC into BeWo cells. The quan-
tification of green fluorescence outside and inside Bewo
cells from pictures of figure 4 is presented on figure 5Aand
5Brespectively. T20 dramatically increased the quantity of
green fluorescence (in pixels) transferred into the cyto-
plasm of CD4 negative BeWo cells (p = 0.03). The same
experiments were performed in parallel with CD4 positive
BeWo cells, as shown on figures 6 and 7. The difference in
fusion/adhesion in the presence or not of T20 was not sta-
tistically significant, corroborating the observations from
figure 3. As controls, slides were performed in the pres-
ence of 800 nM AMD3100 (column on the right of fig-
ures 4and 6). AMD3100 blocked HIV-1 LAI infected
PBMC outside CD4 positive BeWo cells (figure 7A).
Experiments from figures 4, 5, 6 and 7 revealed that the
enhancement of X4 virus passage by T20 we observed in
the double chamber system was in fact due to an increase
in cell fusion. The quantification (Figure 5 &7) in light
units of green fluorescence outside BeWo cells (hence still
inside infected PBMC) (Figure 5Aand 7A) and inside
BeWo cells (Figure 5Band 7B) is consistent with this
scheme. Green fluorescence inside BeWo cells (Figure 5B)
was dramatically significantly increased only in CD4 neg-
ative BeWo cells.
At this point, we concluded that T20, by increasing the
fusion of PBMCs infected with HIV-1/LAI on BeWo cells,
facilitated the entry of the virus into these target cells espe-
cially in wildtype BeWo cells which do not express CD4 at
their surface.
T20 efficiently blocks viral passage across a human 
placenta-derived cell line monolayer in contact with CD4+ 
T cells infected by the X4 HIV-1/LAI
PBMCs are constituted of various cell types acting on each
other either by direct cell-to-cell interaction, or via soluble
factors such as cytokines. In a further attempt to identify
on which of these two alternatives T20 acts to increase X4
HIV-1 infected PBMCs passage across the BeWo cell mon-
olayer, we purified CD4 positive T cells from PBMCs
(from the same batch used in experiments above) and
infected them with HIV-1 LAI. We then performed the
contact with the BeWo cell monolayer in our in vitro
model in the same conditions as with PBMCs.
Results from this experiment showed that T20 was highly
efficient to block viral passage when BeWo cells were in
contact with purified CD4 positive T cells infected with
the X4 HIV-1/LAI (figure 8). In this situation, the IC50
and IC90 observed were 1,200 nM and 2,000 nM, respec-
tively. A complete blockade of viral passage was observed
at T20 concentration below 5,000 nM (figure 8). From
this experiment, we concluded that cell types other than
CD4 positive T-cells present in PBMCs are responsible,
either directly, or indirectly through soluble factors, of
T20 increase of X4 viral passage across the BeWo cell mon-
olayer.
A soluble factor secreted by CD4 negative cells from 
PBMCs contributes to the increase of viral passage 
through the BeWo cells monolayer by T20
The experiment with purified CD4 positive T cells was
then performed in the presence of either culture medium
as diluent (like on figure 8), or 24-hours culture superna-
tants from HIV-1 LAI infected PBMCs, 24 hours culture
supernatant of uninfected PBMCs, or of 24 hours superna-
tant of CD4 negative cells from uninfected PBMCs.
Results from these experiments are reported on figure 9.
These results confirm that T20 is highly potent in blocking
HIV-1/LAI transfer between infected purified CD4 posi-
tive T-cells and BeWo cells monolayer. Upon addition of
24 hours culture supernatant of PBMCs (infected or not)
or of CD4 negative cells from PBMCs, the enhancement of
viral passage by T20 was restored, in a dose dependent
manner, since less diluted supernatants contribute to
higher increase of fusion. These results indicate that a sol-
uble factor secreted by CD4 negative cells present in the
PBMC pool contributes to the enhancement of viral pas-
sage across the BeWo monolayer by T20.Page 7 of 18
(page number not for citation purposes)
Retrovirology 2008, 5:31 http://www.retrovirology.com/content/5/1/31Discussion
The present report shows that CCR5 antagonists and
fusion inhibitors block, but with a moderate efficacy, HIV-
1 cell-to-cell transmission during the contact between R5
or R5X4 infected PBMCs in contact with a polarized mon-
olayer of BeWo cells. The CXCR4 antagonist evaluated in
the present study also potently inhibited HIV-1 transmis-
sion from X4-viruses infected PBMCs interacting with
BeWo cells. All these drugs were efficient with IC50 in the
range of 4 to 20,000 nM. The present study also uncovered
an intriguing feature of T20 that we found to increase the
transmission of X4 viruses in our in vitro model of interac-
tion between BeWo/PBMC-HIV-1X4 that mimics the
human trophoblast barrier.
The fusion inhibitor T20 significantly enhances target CD4 negative BeWo cells-HIV-1/LAI infected PBMCs fusionFigure 4
The fusion inhibitor T20 significantly enhances target CD4 negative BeWo cells-HIV-1/LAI infected PBMCs 
fusion. Target CD4 negative BeWo cells (2 × 104/well) were coated overnight on slides as described in the method section. 
Target cells were then pre-incubated with indicated doses of AMD3100 or T20, or without drug, for 30 minutes at 37°C. At 
this point, calcein-AM loaded, HIV-1 LAI infected PBMCs were added ant left to interact for 5 h at 37°C. Slides were then 
washed and the cells fixed. The nuclear dye DAPI was then added into the wells for 5 min and washed out afterwards. The 
slides, once dried, were mounted in the presence of an antifade reagent at left to cure overnight at +4°C, in the dark. The day 
after, slides were observed under fluorescent microscope (20× magnification) and the images captured. Phase contrast images 
were also captured. The figure shows representative microscope fields of 2 (no drug or AMD3100) or 4 different wells (T20) 
for each experimental conditions tested. Row 1: Calcein stain; row 2: DAPI stain; row 3: merge of 1 and 2; row 4: phase con-
trast images. The green spots and green areas are intact PBMCs and their fused cytoplasm with BeWo cells, respectively. The 
blue spots are cell nuclei coloured by DAPI.Page 8 of 18
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is more efficient than cell-free virus infection of permis-
sive cells [37]. Thus, our data on increased IC50s of T20,
TAK779, SCH-350581 to block R5 and R5X4 HIV-1 cell-
to-cell transmission as compared to cell-free PBMC infec-
tion is consistent with these observations.
The fusion inhibitor T20 quantitatively increases transfer of green fluorescence from the effector to target CD4 negative BeWo cell cytoplasmsFigure 5
The fusion inhibitor T20 quantitatively increases transfer of green fluorescence from the effector to target 
CD4 negative BeWo cell cytoplasms. Green fluorescence from the experiment on slides (figure 4) was quantified in light 
units (pixels) inside and outside CD4 negative BeWo cells. Figure 5A (upper panel) represents the green fluorescence in 
PBMCs that have adhered on the surface of BeWo cells (outside). Figure 5B (lower panel) represents green fluorescence that 
has been transferred from HIV-1 LAI infected PBMCs into BeWo cells (inside). The figure shows averaged green fluorescence 
intensities from 3 differents fields in the absence of drug, in the presence of 10 μM T20 or 800 nM AMD3100. Histograms rep-
resent means and the error bars are standard deviation to the mean.Page 9 of 18
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The fusion inhibitor T20 moderately enhances target CD4 positive BeWo cells-HIV-1/LAI infected PBMCs fusionFigure 6
The fusion inhibitor T20 moderately enhances target CD4 positive BeWo cells-HIV-1/LAI infected PBMCs 
fusion. Target CD4 positive BeWo cells (2 × 104/well) were coated overnight on slides as described in the method section. 
Target cells were then pre-incubated with indicated doses of AMD3100 or T20, or without drug, for 30 minutes at 37°C. At 
this point, calcein-AM loaded, HIV-1 LAI infected PBMCs were added ant left to interact for 5 h at 37°C. Slides were then 
washed and the cells fixed. The nuclear dye DAPI was then added into the wells for 5 min and washed out afterwards. The 
slides, once dried, were mounted in the presence of an antifade reagent at left to cure overnight at +4°C, in the dark. The day 
after, slides were observed under fluorescent microscope (20× magnification) and the images captured. Phase contrast images 
were also captured. The figure shows representative microscope fields of 2 (no drug or AMD3100) or 4 (T20) different wells 
for each experimental conditions tested. Row 1: Calcein stain; row 2: DAPI stain; row 3: merge of 1 and 2; row 4: phase con-
trast images. The green spots and green areas are intact PBMCs and their fused cytoplasm with BeWo cells, respectively. The 
blue spots are cell nuclei coloured by DAPI. The figure shows moderate enhancement of viral passage by T20 on CD4 positive 
BeWo cells.
Retrovirology 2008, 5:31 http://www.retrovirology.com/content/5/1/31The two CCR5 antagonists failed to inhibit PBMC infec-
tion with the dualtropic isolate A204, but were efficient,
though at high concentrations, to block cell-to-cell viral
transmission of the same isolate. This difference could be
explained by the homogeneity of BeWo cells, as compared
to the mixture of cell populations with different proper-
ties present in PBMCs preparation. It has been recently
shown a preferential use of CXCR4 by R5X4 HIV-1 isolates
in primary lymphocytes [35]. In the present study, we
characterized by a functional assay [38], the coreceptor
The fusion inhibitor T20 does not quantitatively increases transfer of green fluorescence from the effector to target CD4 pos-itiv  Bewo cell cytoplasmsF gur  7
The fusion inhibitor T20 does not quantitatively increases transfer of green fluorescence from the effector to 
target CD4 positive Bewo cell cytoplasms. Green fluorescence from the experiment on slides (figure 6) was quantified in 
light units (pixels) inside and outside CD4 positive BeWo cells. Figure 7A (upper panel) represents the green fluorescence in 
PBMCs that have adhered on the surface of BeWo cells (outside). Figure 7B (lower panel) represents green fluorescence that 
has been transferred from HIV-1 LAI infected PBMCs into BeWo cells (inside). The figure shows averaged green fluorescence 
intensities from 3 differents fields in the absence of drug, in the presence of 10 μM T20 or 800 nM AMD3100. Histograms rep-
resent means and the error bars are standard deviation to the mean. There is no difference statistically significant between the 
three different conditions compared (no drug, +T20, +AMD3100).Page 11 of 18
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Retrovirology 2008, 5:31 http://www.retrovirology.com/content/5/1/31usage of the clinical isolate A204. Of the 20 clones we ana-
lyzed, all were able to use both CCR5 and CXCR4 to infect
U87.CD4-CXCR4 or U87.CD4-CCR5 (data not shown).
Another feature of the two CCR5 antagonists is the differ-
ence in their distinct efficacies to block cell-free HIV-1
PBMC infection and cell-to-cell transmission of the virus
in our system. The IC50 for SCH-350851 necessary to
block BeWo/PBMC-HIV-1 Ba-L passage is 18 to 22 folds
higher than that needed to inhibit HIV-1 Ba-L/PBMC
infection. On the contrary, for TAK779, only 1 to 1.5
times more drugs were needed to achieve 50% inhibition
of BeWo/PBMC-HIV-1 Ba-L passage. The difference could
be due to particular physico-chemical properties of the
molecules, or to a subtle difference in the mode of action
of the two molecules. It has been shown that both drugs
inhibit infection of PBMCs by R5 viruses by binding to
various amino acids residues of the transmembrane
domains 1, 2, 3, 5 and 7 of the CCR5 molecule, prevent-
ing viral entry [39,40]. Given these latter observations, the
difference in activity we observed between the two CCR5
antagonists should lay in their intrinsic physico-chemical
properties rather than the targets amino-acids on the
CCR5 molecule.
The fusion inhibitor T20 inhibits viral passage across the BeWo monolayer in contact with HIV-1/LAI infected CD4+ T cellsFigure 8
The fusion inhibitor T20 inhibits viral passage across the BeWo monolayer in contact with HIV-1/LAI infected 
CD4+ T cells. The experiment was designed as described for figure 3, except that purified CD4 positive T cells were used as 
effector cells, instead of whole PBMCs, for infection with HIV-1 LAI. The figure shows a dose-dependent inhibition of the inter-
action between BeWo-CD4 negative target cells and CD4+ T cells infected with HIV-1/LAI.Page 12 of 18
(page number not for citation purposes)
Retrovirology 2008, 5:31 http://www.retrovirology.com/content/5/1/31In line with published data obtained with different infec-
tion systems, our data here show that the prototype
CXCR4 antagonist AMD3100 can also efficiently inhibit
the viral passage across the BeWo cell monolayer in con-
tact with PBMCs infected by X4 or R5X4 HIV-1. Given the
progressive emergence of X4 viruses in the course of AIDS
disease even under HAART [41], the availability of a
potent CXCR4 antagonist as part of salvage therapy is of
utmost interest. However, AMD3100 does not seem to be
the best candidate for this purpose because of its paucity
in reducing plasma viral load in a clinical trial [42]. A con-
cern also remains on the effects of AMD3100 on haemat-
opoiesis, as this molecule has been shown to be a
powerful and fast mobilizer of CD34+ progenitor cells,
beside its potential anti X4-HIV-1 activity [43].
The mechanism by which T20 blocks HIV-1/target cell
membrane fusion has been extensively explored [44,45].
A soluble factor secreted by CD4 negative cells from PBMCs contributes to the increase of viral passage through the BeWo cell monol yer by T20Figure 9
A soluble factor secreted by CD4 negative cells from PBMCs contributes to the increase of viral passage 
through the BeWo cell monolayer by T20. Purified CD4+ T-cells were infected with HIV-1/LAI and used as effector 
cells, as in the experiment from figure 8. Different media were used as diluent for cells and T20 during the contact with CD4 
negative BeWo cells. The media used were either normal culture medium (M) (RPMI 1640 medium), or in 1) 24 h culture 
supernatant of HIV-1 LAI infected PBMCs, 2) 24 h culture supernatant of uninfected PBMC or 3) 24 h culture supernatant of 
CD4 negative cells from PBMCs. The figure shows p24 Ag produced in basolateral chamber at day 8 post contact in these dif-
ferent conditions. The histograms are means (with standard deviations to the means) of values from three different wells of 
one experiment out of two.Page 13 of 18
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Retrovirology 2008, 5:31 http://www.retrovirology.com/content/5/1/31The general consensus is that T20 (and C34) are effective
once HIV-1 gp120-CD4 has taken place, inducing a con-
formational change of the heterodimer gp120-gp41 [36].
This conformational change allows, to its turn, the expo-
sition of otherwise masked regions of gp41, especially the
N- and C-terminal Heptad repeats (NHR and CHR,
respectively) domains [36,46]. This so-called pre-hairpin
intermediate is stable enough to be targeted by antibodies
and inhibitors [47]. Instead of the normal interaction
between N- and C-terminal HRs to yield a six-helix bundle
for membrane fusion and viral genetic material transfer
into the host cell, T20 (and C34) binds to the NHR, pre-
venting the formation of the six helix bundle and thus
membrane fusion. Our present results with HIV-1 Ba-L
and HIV-1 A204 are consistent with that model for BeWo-
CD4 positive cells, as a dose-dependent inhibition of viral
entry was observed, though with IC50s that are 1,000 fold
higher than those reported for classical HIV-1/PBMC
infection. Half maximal inhibitory concentrations (3–5
μM for CD4 negative target cells) remain, however, in the
range of T20 pharmacokinetics values with standard sub-
cutaneous dose of 90 mg twice daily [48]. The fact that
T20 was efficient in preventing R5 and R5X4 passage even
if the target BeWo cells were CD4 negative suggests that
another mechanism of inhibition distinct from the one
outlined above might be involved in the context of HIV-1
cell-to-cell transmission. This alternative mechanism of
T20 action during HIV-1 R5 and R5X4 infected PBMC and
CD4 negative BeWo cells, might imply other receptors like
Galactosyl Ceramide, expressed on the surface of these
cells [49,50]. Although efficient, though at high concen-
trations, on R5 and R5X4 viruses, T20 was not effective in
blocking viral passage in X4 HIV-1 infected PBMC in inter-
action with BeWo cells. Rather, T20 (and C34), enhanced
it.
This enhancement of X4 HIV-1 passage by T20 and C34
following cell-to-cell contact was unexpected. This
enhancement is CD4 independent. In a recent work by
Blanco and colleagues [51], a high level of coreceptor-
independent HIV transfer was observed between primary
CD4+ T-cells. This transfer was enhanced up to 300 folds
by C34 but also by the CXCR4 antagonist AMD3100. The
enhancement was only observed with the X4 virus NL4-3.
Our present observations are different in the way that
AMD3100 blocked viral passage across the BeWo cell
monolayer in contact with X4 HIV-1 infected PBMCs. We
cannot, however, exclude that AMD3100 could also
increase X4 HIV-1 passage in our model at higher doses
(10 μg/ml) like in the work reported by Blanco and col-
leagues. Also, entry enhancement we observed is corecep-
tor dependent and CD4-independent, the exact opposite
of transfer enhancement reported by Blanco and col-
leagues. It has also been shown that X4 virus were more
sensitive to inhibition by T20 and C34 in cell-free PBMC
infection [52]. This higher sensitivity of X4 virus to fusion
inhibitors is thought to lay, at least in part, to the direct
interaction of T20, but not C34, with the CXCR4 molecule
on the cell surface [52]. This "chemokine" aspect of T20
needs further investigation, complementary to published
data [53].
From our results, we cannot exclude a direct interaction of
T20 with CXCR4 present on target BeWo cells because the
enhancement was only observed with X4 virus and could
be inhibited in the presence of AMD3100 (not shown).
This entry enhancement was not due to the polarized state
of BeWo cells, as we had similar observations with non-
polarized cells on slides. Rather, T20 (and C34), could
first attract effector cells infected with an X4 HIV-1
towards target cells, followed by an increased of cell-
membrane fusion. It has been reported that T20 can act as
a chemo attractant of monocytes, but not of lymphocytes
[54]. This observation partly justifies our experiment with
purified CD4 positive T cells.
Interestingly, when we used these purified CD4 positive T
cells (instead of PBMCs) infected with HIV-1/LAI as effec-
tor cells in our system, T20 was found to be highly potent
in inhibiting viral passage across the BeWo monolayer
(Fig. 8). The enhancement of viral passage across the
BeWo monolayer by T20 could thus be a result of direct
interaction between X4 HIV-1 infected CD4+ T cells,
another cell population (CD4 negative) within the
PBMCs and the BeWo cells. Alternatively, enhancement of
X4 HIV-1 passage by T20 and C34 could be due to the syn-
ergistic effect of T20 (and C34) and a soluble factor
secreted par CD4 negative cells present in the PBMCs. In
our last experiment (9), 24h-cultures supernatants from
CD4 negative cells were added during the interaction
between CD4 positive T cells infected with HIV-1/LAI and
CD4 negative BeWo cells. In these conditions, the enhanc-
ing effect of T20 was restored, suggesting that a soluble
factor secreted by CD4 negative cells contributes to the
increase of X4 HIV-1 passage in the presence of T20. These
findings need, however, further investigations.
The precise mechanism by which the two C-terminal Hep-
tad Repeat peptides (T20 and C34) enhanced X4 HIV-1
passage across the BeWo cell monolayer remains to be
elucidated. However, this observation is of real concern, if
confirm by others, with regards to HIV-1 transmission at
the level of epithelial surfaces, during sexual or mother-to-
child transmission for example, in patients under Enfuvir-
tide therapy. Other abnormal peculiarities of HIV-1 in the
presence of T20 have been reported. Some HIV-1 strains
whose abnormal envelope folding, leading to viruses una-
ble to properly matured, were rescued by T20 addition
[55].Page 14 of 18
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is very limited to date. Recently however, studies reported
the use of T20, on a backbone of combined therapies [56-
58]. The study by Cohan and colleagues reported the case
of a mother infected with a multidrug resistant HIV-1 and
who transmitted the virus to her child, despite plasma
viral load suppression by T20 treatment. The phenotype
of the transmitted virus was not discussed, but the eight
clones randomly selected and sequenced in gp41 HR1
and HR2 were all T20 sensitive. The study by Brennan-
Benson and co-workers, reported on two cases of pregnant
women infected by multidrug resistant HIV-1, with the
delivery of two uninfected children. The plasma viral load
was fully suppressed for one case and lowered down to
300 copies/ml for the other. In this study too, the viral
phenotypes were not discussed. The other interesting
observation from this study is the lack of transplacental
passage of T20. Thus, from these studies, it is difficult to
conclude on the potency of T20, with a weak if any, trans-
placental transfer, in preventing HIV-1 mother-to-child
transmission.
Conclusion
Our in vitro data showed that HIV-1 co-receptor antago-
nists (TAK779, SCH-350581 and AMD3100) are active at
high doses to block viral passage during cell-to-cell con-
tact across a monolayer of placenta-derived cell line in
contact with PBMCs infected with R5, R5X4 and X4
viruses. HIV-1 entry inhibitors are less efficient, in vitro, to
block cell-to-cell virus transmission than cell-free HIV-1
infection of PBMCs and CCR5 antagonists do not prevent
PBMC infection by dual tropic HIV-1 in contrast to cell-to-
cell infection in our model. Further steps of evaluating
these molecules include the assessment of the compatibil-
ity of these high doses of drugs with the placental tissue
viability ex vivo. The finding that T20 was less potent than
expected on R5 and R5X4 viruses and counterproductive





The human choriocarcinoma BeWo cell line (ATCC CCL
98) [59] was obtained initially from the American Type
Culture collection (Rockville, MD). The cells were main-
tained in Dulbecco's modified Eagle medium (GIBCO,
Invitrogen SARL, Cergy Pontoise, France) containing glu-
cose (25 mM), supplemented with 20% heat-inactivated
foetal calf serum (GIBCO), 20 mM L-Glutamine, 50IU
penicillin and 50 μg/ml streptomycin at 37°C, in 5% CO2
humidified atmosphere. A sub-cell line expressing the
CD4 molecule on the cell surface was generated by trans-
fection of this primary cell line, with the plasmid contain-
ing the human CD4 sequence (PCMV/CD4SrpuroR) as
previously described [31]. Human Peripheral Blood
Mononuclear Cells (PBMCs) were prepared from venous
blood of healthy donors (Etablissement Français du Sang,
Rungis, France. Habilitation #HS2003-5240) on Ficoll
gradient (PAA laboratories, Les Mureaux, France) and
used either to produce virus stocks, or as effector or as
indicator cells. PHA-stimulated PBMCs were cultivated in
RPMI1640 medium supplemented with 10% heat-inacti-
vated foetal calf serum and 100 IU/ml of recombinant
human IL-2 (Chiron B.V. Amsterdam, The Netherlands).
Viruses
The viral isolate HIV-1 Ba-L (R5), a primary isolate of HIV-
1 LAI (X4), the clinical isolate HIV-1 A204 (R5X4) from a
mother who transmitted in utero the virus to her child [60]
and HIV-1 KH025 (X4) from a Cambodgian patient [61],
were used throughout the work.
Entry inhibitors
The following reagents were obtained through the NIH
AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID, NIH: AMD3100, CXCR4 antagonist, rea-
gent #8128; TAK779, CCR5 antagonist, reagent#4983,
T20, fusion inhibitor, reagent#9845 and C34, fusion
inhibitor, reagent#9824. The CCR5 antagonist SCH-
350581 [40] was kindly provided to us by Schering-
Plough Research Institute (Kenilworth, NJ).
Methods
Cell cultures
Human PBMCs, BeWo cell lines (either expressing at their
surface the CD4 molecule or not) were cultured as
described previously [4]. The level of CD4 expression on
BeWo cells was systematically controlled by flow cytome-
try before seeding on Transwell® inserts by using an anti-
CD4 antibody labelled with PC5 dye (Beckman-Coulter,
Villepinte, France). The level of surface CD4 expression on
BeWo-CD4+ cells was always between 15 and 40%. The
U87 cell line transfected to stably express CD4 (U87-
CD4) [31] on cell surface was used as positive control.
Purification of CD4+ T cells
CD4 positive T cells were purified from a healthy donor's
PBMCs, by positive selection with an anti-CD4 labelled
magnetic beads (Miltenyi Biotec Inc. Auburn, CA, USA)
followed by negative selection with an anti-CD14 labelled
magnetic beads (Dynal Biotech ASA. Oslo, Norway). Cells
obtained were > 98% CD3+/CD4+ T-cells as confirmed by
flow cytometry.
Inhibition by different ARVs of PBMC infection with cell-free HIV-1
To verify biological activities of the different coreceptor
antagonists in a known system, 105 PHA stimulated
PBMCs were pre-incubated for 30 min in the presence of
variable doses of the different entry inhibitors, thenPage 15 of 18
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Retrovirology 2008, 5:31 http://www.retrovirology.com/content/5/1/31infected with the different viral isolates at multiplicity of
infection (MOI) of 10-3 and 5 × 10-3 for one hour. For the
inhibition with fusion inhibitors, the different viral iso-
lates, at 10-3 and 5 × 10-3 MOI, were first pre-incubated
with the drugs for 30 mn before the contact with PBMCs
as for inhibition with coreceptor antagonists. Cells were
then washed 3 times with RPMI1640 (GIBCO) and plated
in the presence of the same concentration of entry inhibi-
tor they were pre-incubated with. After 3 days at 37°C,
supernatants were collected and replaced with fresh
medium containing IL-2, without drug, until day 7. Cul-
tures were then stopped and viral production checked by
p24 antigen ELISA (Beckman-Coulter) quantification in
the supernatants.
Inhibition of cell-to-cell infection by entry inhibitors
CD4+ and CD4- BeWo cells (target cells) were seeded at
2.5 × 105 and 5 × 105 per cm2, respectively, in the inserts
of a 12-well Transwell® system (Corning SA, Avon,
France), five days before the contact with infected PMBC
(effector cells). Preliminary experiments have indeed
shown that the two cell lines of BeWo present different
growth kinetics. The day of contact, BeWo cells on the
Transwell® insert (apical and basolateral chambers) were
equilibrated in RPMI1640 medium containing IL-2 for
1–2 h, then pre-incubated for 30 min with variable doses
of coreceptor inhibitors. Then, HIV-1 (Ba-L, LAI, A204 or
KH025) infected PBMCs (day 8 post infection), were
equilibrated in the drug solution at appropriate concen-
tration, and added at the apical chamber of the Transwell®
system and incubated 3 h at 37°C. For inhibition with
fusion inhibitors, effector cells were pre-incubated with
the drugs (37°C, 30 mn) before the contact with target
cells. For CD4+ and CD4- BeWo cells, 5 × 105 and 106
infected PBMCs were added, respectively. Thus, the effec-
tor-to-target ratio of 2 remains the same for the two cell
lines. At the end of the 3 h contact period, the inserts were
transferred onto new 12-well plates containing fresh
RPMI1640 medium without IL-2 and extensive washings
(up to seven, including a 1 minute trypsin treatment) were
performed. After the last washing, inserts were transferred
onto wells containing 1.5 × 106 PHA stimulated HIV neg-
ative PBMCs as indicator cells in culture medium with IL-
2. No inhibitor was added. In experiments with purified
CD4+ T-cells, 24 h cultures supernatants of uninfected
PBMCs, or LAI-infected PBMCs or uninfected CD4+ T-cell
depleted PBMCs, were used as diluents for T20 and cells
during the contact period. Inserts were left on indicator
cells for 5 days, with half of apical and basolateral media
changed by fresh RPMI1640+IL-2 medium at day 2 post-
contact. At day 5, the inserts were removed, controlled for
the integrity of BeWo cells monolayer visually and by the
Evans blue passage test, as previously described [4]. Half
the volume of supernatants from the basolateral cham-
bers were harvested and replaced by fresh RPMI1640+IL-
2 medium. This was repeated at day 8 and 12 post-contact
and viral production in the supernatants was checked by
p24 antigen quantification.
Fluorescent dye transfer experiments
These experiments were performed on 8-well LABTEK
slides (Nalge Nunc International, Rochester, NY). Slides
were coated overnight at 4°C with 10% bovine collagen
in PBS (Sigma Aldrich Chemical Co., L'Isle d'Abeau
Chesnes, France) and then washed 3 times with PBS, air-
dried, and kept at room temperature until use.
2 × 104 BeWo cells (CD4- or CD4+) in 200 μl of medium
were seeded per well for 24 h at 37°C, 5% CO2. The pro-
tocol used was adapted from the one by Weiss et al [62].
Human PBMCs, at day-7 post infection with HIV-1 LAI,
were labelled with the green cytoplasmic dye calcein-AM
(Sigma-Aldrich) at 1.5 μg/ml in PBS. After 30 minutes of
labelling, cells were washed extensively with PBS and used
as effector cells. Two hours before the contact between
effector cells (HIV-1 infected PBMCs) and target cells
(BeWo cells), the latter were equilibrated in RPMI1640
medium containing IL-2. The contact was performed at an
effector-to-target ratio of 3 (a titration was performed in
the range of 1–5 E:T ratios) in the presence or not of drugs.
Cells were left in contact for 4 h at 37°C, 5% CO2. After
the 4 hours, cells were fixed with 2% (v/v) Paraformalde-
hyde in PBS for 30 mn at room temperature, washed 3
times with PBS, air-dried and counterstained with the
nuclear dye 4'-6'-diamidino-2-phenylindole, dihydro-
chloride (DAPI), FluoroPure™ grade (Molecular Probes,
Eugene, OR) at a final concentration of 300 nM in PBS for
5 min. The slides were then washed with PBS and
mounted in the presence of the anti-fade ProLong® Gold
Antifade Reagent (Molecular Probes, Eugene, OR) and left
to cure overnight at 4°C in the dark before viewing. Slides
were viewed on a Nikon FXA fluorescent microscope at
20× (objective) and 10× (ocular). The microscope was
coupled to a Nikon D1 numeric Camera. Images were cap-
tured on an Apple® PowerMacintosh® computer by using
the Nikon Capture® and Adobe Photoshop® softwares.
Green fluorescence was quantified in light units (pixels)
inside (fusion) and outside (adhesion) BeWo cells from 3
different fields for each experimental conditions: in the
absence of drug, in the presence of 10 μM T20 or 800 nM
AMD3100.
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